The specter of generic rivalry has consistently loomed around copyright’s blockbuster drug, PDE5 Inhibitor, raising questions about the outlook of similar drug investments. While early periods saw impressive gains, the intellectual property lapse has allowed the door for discounted alternatives, potentially reducing profitability and posing a sig